The latest selling price per box of Entrectinib in 2025

Entrectinib (Entrectinib) is a targeted drug that is mainly used to treat tumors with ROS1 and NTRK gene fusions, especially in advanced cancers such as non-small cell lung cancer. It has shown significant therapeutic effects. Compared with traditional treatment methods, entrectinib effectively prevents the spread and proliferation of tumor cells by precisely inhibiting the abnormal activity of specific gene mutations, and has become one of the important drugs in the era of precision medicine.

The original drug of entrectinib is available in capsule form in the domestic market. The common specifications are: 100mg 30 capsules and 200mg 90 capsules. The price of each box is about more than 20,000 yuan. Although entrectinib on the domestic market has been included in the scope of medical insurance reimbursement, and eligible patients can obtain certain cost subsidies through medical insurance, the cost of the drug is still a considerable burden for some patients with heavy financial burdens.

The price of entrectinib in overseas markets is relatively higher, especially in the European market.The price of the original drug of 200 mg and 90 tablets may be as high as more than 40,000 yuan. This price may fluctuate due to factors such as exchange rates. Compared with the original drug, there are also generic entrectinib drugs from Laos and other countries on the market. The ingredients of these generic drugs are basically the same as the original drug, and the price is relatively affordable. For example, the price of a 100mg 60-capsule generic drug produced by a Lao pharmaceutical factory is about more than 1,000 yuan, which is suitable for some patients with tight budgets.

In general, entrectinib, as a precision targeted therapy, has significant efficacy and good tolerability in the treatment of tumor patients with ROS1 or NTRK gene mutations. Although its price is higher, with the emergence of generic drugs, patients have more choices when choosing. As market competition intensifies, the price of entrectinib is expected to fall further, improving treatment accessibility for more patients.

Reference materials:https://www.roche.com/products/rozlytrek